# Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer

> **NCT00038428** · PHASE2 · COMPLETED · sponsor: **Telik** · enrollment: 40 (—)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** TLK286

## Key facts

- **NCT ID:** NCT00038428
- **Lead sponsor:** Telik
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** 2005-07
- **Final completion:** 2005-07
- **Target enrollment:** 40 (—)
- **Last updated:** 2011-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00038428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00038428, "Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00038428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*